Authors:
Nuijen, B
Bouma, M
Talsma, H
Manada, C
Jimeno, JM
Lopez-Lazaro, L
Bult, A
Beijnen, JH
Citation: B. Nuijen et al., Development of a lyophilized parenteral pharmaceutical formulation of the investigational polypeptide marine anticancer agent kahalalide F, DRUG DEV IN, 27(8), 2001, pp. 767-780
Authors:
Nuijen, B
Bouma, M
Manada, C
Jimeno, JM
Lazaro, LL
Bult, A
Beijnen, JH
Citation: B. Nuijen et al., Compatibility and stability of the investigational polypeptide marine anticancer agent kahalalide F in infusion devices, INV NEW DR, 19(4), 2001, pp. 273-281
Authors:
Nuijen, B
Bouma, M
Henrar, REC
Brauns, U
Bette, P
Bult, A
Beijnen, JH
Citation: B. Nuijen et al., In vitro biocompatibility studies with the experimental anticancer agent BIBX1382BS, INT J PHARM, 194(2), 2000, pp. 261-267
Authors:
Nuijen, B
Bouma, M
Henrar, REC
Manada, C
Bult, A
Beijnen, JH
Citation: B. Nuijen et al., Compatibility and stability of aplidine, a novel marine-derived depsipeptide antitumor agent, in infusion devices, and its hemolytic and precipitation potential upon i.v. administration, ANTI-CANC D, 10(10), 1999, pp. 879-887
Authors:
Bouma, M
Dekker, JH
van Eijk, JTM
Schellevis, FG
Kriegsman, DMW
Heine, RJ
Citation: M. Bouma et al., Metabolic control and morbidity of Type 2 diabetic patients in a general practice network, FAM PRACT, 16(4), 1999, pp. 402-406
Authors:
Bouma, M
Dekker, JH
de Sonnaville, JJ
van der Does, FE
de Vries, H
Kriegsman, DM
Kostense, PJ
Heine, RJ
van Eijk, JT
Citation: M. Bouma et al., Now valid is fasting plasma glucose as a parameter of glycemic control in non-insulin-using patients with type 2 diabetes?, DIABET CARE, 22(6), 1999, pp. 904-907
Authors:
Rowland, M
Durrani, N
Hewitt, S
Mohammed, N
Bouma, M
Carneiro, I
Rozendaal, J
Schapira, A
Citation: M. Rowland et al., Permethrin-treated chaddars and top-sheets: appropriate technology for protection against malaria in Afghanistan and other complex emergencies, T RS TROP M, 93(5), 1999, pp. 465-472